ABSTRACT: Acute coronary syndromes (ACS) frequently cause considerable morbidity and mortality with a high risk of further events within the following year, despite the use of percutaneous coronary intervention (PCI). Numerous studies have described the concept of acute, partial or complete thrombotic occlusion of the coronary artery, which occurs at the site of a friable atherosclerotic plaque with a lipid-rich necrotic core and a ruptured overlying thin fibrous cap (“culprit lesion”).
ABSTRACT: Background. The optimal combination of anticoagulant and antiplatelet therapy following percutaneous coronary intervention with stenting (PCI-S) among patients requiring oral anticoagulation (OAC) is unknown. Objectives
ABSTRACT: Objectives. Compare outcomes of hybrid bare-metal stent (BMS)/sirolimus-eluting stent (SES) to BMS alone for the treatment of stenoses in small coronary arteries
Mitral regurgitation (MR), a common valvular disorder, is a heterogeneous condition that can be broadly categorized into primary (affecting the valve apparatus) or secondary (functional) etiologies. For appropriately selected patients, surgical mitral valve repair, when possible, is the preferred strategy over mitral valve replacement. 1 The evidence for device/surgical treatment of functional mitral regurgitation is less well established for patients with severe heart failure and conveys increased operative risk
ABSTRACT: Background. The coronary sinus (CS) travels in close proximity to the left circumflex (LCX) artery. Percutaneously placed CS devices used to treat mitral regurgitation (MR) therefore have the potential to impinge upon the LCX arterial distribution and compromise coronary flow
ABSTRACT: Objective. To examine the 1-year safety and clinical outcomes associated with the post-marketing early unselected use of sirolimus-eluting stents (SES) in the United States
There are no submissions added yet, be the first.
Loading...